MTOR and acute lymphoblastic leukemia: Through testing ICG-001 on T-ALL cell lines (CEM-S, JURKAT, HPB-ALL, MOLT-4, RPMI-8402), Evangelisti et al. demonstrated that simultaneous targeting of the Wnt/β-catenin pathway using ICG-001, and the PI3K/Akt/mTOR axis with ZSTK-474, a PI3K inhibitor, effectively reduced the proliferation, survival, and clonogenic activity of T-ALL cells [158].